Evaluation of Potential Drug-Drug Interactions in Patients Taking HMG CoA-reductase Inhibitors
![]() |
Lee, Kyeong Ju
(Department of Clinical Pharmacy, College of Pharmacy, Kangwon National University)
Kim, Kyung Rim (Department of Clinical Pharmacy, College of Pharmacy, Kangwon National University) Seong, Jae Min (Department of Clinical Pharmacy, College of Pharmacy, Kangwon National University) Ryu, Seung Wan (Department of Clinical Pharmacy, College of Pharmacy, Kangwon National University) Lee, Hyun Yoon (Department of Clinical Pharmacy, College of Pharmacy, Kangwon National University) Cho, Sekyoung (Department of Clinical Pharmacy, College of Pharmacy, Kangwon National University) Cheong, Yeji (Department of Clinical Pharmacy, College of Pharmacy, Kangwon National University) Nam, Ki Nam (Department of Clinical Pharmacy, College of Pharmacy, Kangwon National University) Lee, Yu Jeung (Department of Clinical Pharmacy, College of Pharmacy, Kangwon National University) |
1 | Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058. DOI |
2 | Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 2018;17(1):25-37. DOI |
3 | Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol. 2006;97(8A):61C-8C. |
4 | Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother. 2001;35(9):1096-107. DOI |
5 | Becker ML, Kallewaard M, Caspers PW, et al. Potential determinants of drug-drug interaction associated dispensing in community pharmacies. Drug Saf. 2005;28(5):371-8. DOI |
6 | Shapiro LE, Shear NH. Drug-drug interactions: how scared should we be? CMAJ. 1999;161(10):1266-7. |
7 | Bellosta S, Corsini A. Statin drug interactions and related adverse reactions. Expert Opin Drug Saf. 2012;11(6):933-46. DOI |
8 | Corsini A, Bellosta S. Drug-drug interaction with statins. Expert Rev Clin Pharmacol. 2008;1(1):105-13. DOI |
9 | Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117-25. DOI |
10 | Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol. 2006;97(8A):27C-31C. DOI |
11 | Acharjee S, Welty FK. Atorvastatin and cardiovascular risk in the elderly--patient considerations. Clin Interv Aging. 2008;3(2):299-314. DOI |
12 | Lexicomp. Lexi-comp Inc Web site. Available from https://online.lexi.com. Accessed November 27, 2019. |
13 | Tirkkonen T, Ryynanen A, Vahlberg T, et al. Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study. Drug Saf. 2008;31(3):231-40. DOI |
14 | Zhelyazkova-Savova M, Gancheva S, Sirakova V. Potential statindrug interactions: prevalence and clinical significance. Springerplus. 2014;3:168. DOI |
15 | Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs. 2018;73(15):1681-709. DOI |
16 | Jankovic SM, Pejcic AV, Milosavljevic MN, et al. Risk factors for potential drug-drug interactions in intensive care unit patients. J Crit Care. 2018;43:1-6. DOI |
17 | Ismail M, Iqbal Z, Khattak MB, et al. Potential drug-drug interactions in internal medicine wards in hospital setting in Pakistan. Int J Clin Pharm. 2013;35(3):455-62. DOI |
18 | You JH, Chan WK, Chung PF, et al. Effects of concomitant therapy with diltiazem on the lipid responses to simvastatin in Chinese subjects. J Clin Pharmacol. 2010;50(10):1151-8. DOI |
19 | Lewin JJ, 3rd, Nappi JM, Taylor MH. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann Pharmacother. 2002;36(10):1546-9. DOI |
20 | Mc Donnell CG, Harte S, O'Driscoll J, et al. The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. Anaesthesia. 2003;58(9):899-904. DOI |
21 | Danielak D, Karazniewicz-Lada M, Glowka F. Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins. Drugs. 2018;78(11):1105-12. DOI |
22 | Kariyanna PT, Haseeb S, Chowdhury YS, et al. Ticagrelor and statin interaction induces rhabdomyolysis and acute renal failure: case reports and scoping review. Am J Med Case Rep. 2019;7(12):337-41. DOI |
23 | Mrotzek SM, Rassaf T, Totzeck M. Ticagrelor leads to statininduced rhabdomyolysis: a case report. Am J Case Rep. 2017;18:1238-41. DOI |
![]() |